L\u2019aplicaci\u00f3 cl\u00ednica d\u2019un inhibidor de la prote\u00efna SHP2 (tamb\u00e9 anomenada PTPN11) podria resultar efectiva, en un futur proper, en pacients afectats d\u2019un dels principals tipus de c\u00e0ncer de pulm\u00f3, anomenat Non-small cell lung cancer (NSCLC), el de c\u00e8l\u2022lula no petita. Aquesta \u00e9s la conclusi\u00f3 a la qual ha arribat un equip de recerca internacional, que ha comptat amb la participaci\u00f3 important dels doctors Alberto Villanueva i Ernest Nadal, investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i del programa ProCure de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) a l\u2019Hospitalet de Llobregat.<\/p>\n
\u00a0<\/p>\n
L\u2019\u00fas dels models in vivo avan\u00e7ats de c\u00e0ncer de pulm\u00f3 \u2014anomenats xenoempelts ortot\u00f2pics o Patient-derived orthotopic xenograft (PDOX), consistents en tumors humans implantats en ratolins\u2014, que han desenvolupat en els darrers anys Villanueva i Nadal i que s\u00f3n els m\u00e9s avan\u00e7ats que hi ha avui al m\u00f3n, han resultat una pe\u00e7a crucial en l\u2019elaboraci\u00f3 de l\u2019estudi, recentment publicat a la prestigiosa revista Nature Medicine. Dirigit per Ren\u00e9 Bernards, doctor de The Netherlands Cancer Institute, el treball demostra l\u2019efectivitat d\u2019una nova ter\u00e0pia \u2014actualment en fases primerenques de desenvolupament\u2013 contra els c\u00e0ncers de pulm\u00f3 NSCLC, que s\u00f3n els m\u00e9s prevalents.\u00a0<\/p>\n
\u00a0<\/p>\n
En concret, els investigadors han demostrat que la inhibici\u00f3 d\u2019SHP2\/PTPN11 amb el f\u00e0rmac SHP099, en ratolins amb tumors humans de c\u00e0ncer de pulm\u00f3 i mutaci\u00f3 en el gen K-ras, \u00e9s efectiva. SHP2 t\u00e9 un paper d\u2019enlla\u00e7 entre els receptors tirosina-cinasa (receptors del factor de creixement epid\u00e8rmic, EGFR) de la membrana cel\u2022lular i la via de senyalitzaci\u00f3 RAS-RAF-MEK-ERK, de gran import\u00e0ncia en el desenvolupament dels tumors.\u00a0<\/p>\n
\u00a0<\/p>\n
Aix\u00ed, l\u2019estudi demostra, en el subtipus de c\u00e0ncer de pulm\u00f3 NSCLC estudiat, que l\u2019\u00fas d\u2019aquest nou inhibidor potencia, en els models animals desenvolupats a l\u2019IDIBELL, l\u2019efecte dels inhibidors de la prote\u00efna MEK, ja usats avui dia en el tractament de pacients de c\u00e0ncer de pulm\u00f3 avan\u00e7at. Combinats, ambd\u00f3s tractaments aconsegueixen potenciar la inducci\u00f3 de senesc\u00e8ncia a les c\u00e8l\u2022lules tumorals. Aquesta realitat obre un prometedor futur per a una ter\u00e0pia combinada que resulti efectiva per a l\u2019important grup de pacients de c\u00e0ncer de pulm\u00f3 que s\u00f3n portadors de mutacions en la prote\u00efna K-ras i que, aproximadament, representen el 25 \u2013 30 % dels pacients amb c\u00e0ncer de pulm\u00f3.<\/p>\n
\u00a0<\/p>\n
La rellev\u00e0ncia dels resultats obtinguts gr\u00e0cies, en gran mesura, als experiments de Villanueva i Nadal realitzats en xenoempelts ortot\u00f2pics derivats de tumors dels pacients amb c\u00e0ncer de pulm\u00f3, s\u2019ha vist refor\u00e7ada pel fet que el treball s\u2019ha publicat en paral\u2022lel \u2014i en la mateixa revista cient\u00edfica\u2014 que dos altres articles que hi donen suport i que, en conjunt i des de diferents aproximacions experimentals, defineixen la potencialitat d\u2019aquest nou f\u00e0rmac en el tractament d\u2019altres tumors amb alteracions de l\u2019oncogen K-ras, com el c\u00e0ncer de p\u00e0ncrees i els gastroesof\u00e0gics.<\/p>\n
\u00a0<\/p>\n
La consecuci\u00f3 d\u2019aquest treball ressalta, un altre cop, la rellev\u00e0ncia dels xenoempelts ortot\u00f2pics desenvolupats a l\u2019IDIBELL com a eines fonamentals per identificar nous tractaments, i s\u2019afegeix als \u00e8xits del model experimental, ja aconseguits en altres tipus tumorals. El m\u00e8tode, que consisteix en la implantaci\u00f3 ortot\u00f2pica (\u00e9s a dir, en el mateix \u00f2rgan d\u2019origen) de mostres de tumor humanes en \u00f2rgans de ratolins immunosuprimits, ha estat reconegut internacionalment com un dels models de recerca translacional m\u00e9s avan\u00e7ats i fiables per a l\u2019estudi de noves ter\u00e0pies contra el c\u00e0ncer.
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"
L\u2019aplicaci\u00f3 cl\u00ednica d\u2019un inhibidor de la prote\u00efna SHP2 (tamb\u00e9 anomenada PTPN11) podria resultar efectiva, en un futur proper, en pacients afectats d\u2019un dels principals tipus de c\u00e0ncer de pulm\u00f3, anomenat Non-small cell lung cancer (NSCLC), el de c\u00e8l\u2022lula no petita. Aquesta \u00e9s la conclusi\u00f3 a la qual ha arribat un equip de recerca internacional, que […]<\/p>\n","protected":false},"author":6,"featured_media":10573,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,346],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 21:01:35","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7629"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7629"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10573"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}